Objective-Abdominal aortic aneurysm (AAA) is a vascular disorder characterized by chronic inflammation of the aortic wall. Low concentrations of vitamin D 3 are associated with AAA development; however, the potential direct effect of vitamin D 3 on AAA remains unknown. This study evaluates the effect of oral treatment with the vitamin D 3 receptor (VDR) ligand, calcitriol, on dissecting AAA induced by angiotensin-II (Ang-II) infusion in apoE −/− mice. Approach and Results-Oral treatment with calcitriol reduced Ang-II-induced dissecting AAA formation in apoE −/− mice, which was unrelated to systolic blood pressure or plasma cholesterol concentrations. Immunohistochemistry and reversetranscription polymerase chain reaction analysis demonstrated a significant increase in macrophage infiltration, neovessel formation, matrix metalloproteinase-2 and matrix metalloproteinase-9, chemokine (CCL2 [(C-C motif) ligand 2], CCL5 [(C-C motif) ligand 5], and CXCL1 [(C-X-C motif) ligand 1]) and vascular endothelial growth factor expression in suprarenal aortic walls of apoE −/− mice infused with Ang-II, and all were significantly reduced by cotreatment with calcitriol. Phosphorylation of extracellular signal-regulated kinases 1/2, p38 mitogen-activated protein kinase, and nuclear factor-κB was also decreased in the suprarenal aortas of apoE −/− mice cotreated with calcitriol. These effects were accompanied by a marked increase in VDR-retinoid X receptor (RXR) interaction in the aortas of calcitriol-treated mice. In vitro, VDR activation by calcitriol in human endothelial cells inhibited Ang-II-induced leukocyte-endothelial cell interactions, morphogenesis, and production of endothelial proinflammatory and angiogenic chemokines through VDR-RXR interactions, and knockdown of VDR or RXR abolished the inhibitory effects of calcitriol. Conclusions-VDR activation reduces dissecting AAA formation induced by Ang-II in apoE −/− mice and may constitute a novel therapeutic strategy to prevent AAA progression.
A bdominal aortic aneurysm (AAA) is a localized dilatation of the abdominal aorta and occurs most commonly in ≤9% of adults >65 years of age. 1 The clinical approach to AAA is currently limited to surgical repair and is not indicated in patients with small AAA or who are asymptomatic. Pathological features of AAA include chronic vascular inflammation of the aortic wall, progressive extracellular matrix degradation, and increased neovascularization. 2 Because of the high mortality rate associated with AAA, new effective therapeutic strategies are needed to prevent its progression.
Clinical and experimental data support a role for the reninangiotensin system in AAA pathogenesis. 2 Angiotensin-II (Ang-II), the major effector peptide of renin-angiotensin system, is implicated in both vascular inflammation and pathological vascular growth. [2] [3] [4] Indeed, chronic subcutaneous infusion of Ang-II in apoE −/− mice is a model of AAA formation that shares some characteristic features of human disease, 2, 5, 6 including leukocyte infiltration, chemokine secretion, matrix metalloproteinases (MMPs) release, enhanced new capillary formation, and degradation of the elastic layer of the aortic wall. 4 Although a valuable preclinical model of AAA, increasing evidence indicates that Ang-II-induced lesions in mice should be considered as pseudoaneurysms or dissecting AAA as relevant differences are observed in human AAA, including aneurysm localization and evolution. [7] [8] [9] Epidemiological evidence has established a relationship between low plasma levels of vitamin D 3 and increased risk of cardiovascular disease. [10] [11] [12] More recently, whereas vitamin D 3 deficiency seems to be an independent risk factor associated with thoracic aortic dilatation, 13 an inverse relationship between vitamin D 3 levels and AAA development in humans has been established. 14 The underlying mechanisms explaining these associations, however, are not clearly understood. 14 Calcitriol (1,25-dihydroxyvitamin D 3 ) is the active form of vitamin D 3 , a lipid-soluble vitamin that stimulates absorption of calcium. Beyond its critical function in bone and calcium homeostasis, it also acts on the immune and cardiovascular systems. 15 The binding of calcitriol to the vitamin D receptor (VDR) activates VDR to bind to vitamin D response elements in target genes that are involved in processes of potential relevance to cardiovascular disease. 16 Indeed, VDR activation exerts anti-inflammatory, antiproliferative, and antioxidant properties, which may additionally play important roles in vitamin D 3 -mediated cardiovascular protection. [17] [18] [19] Furthermore, increasing evidence suggests that vitamin D 3 is a potent endogenous regulator of the renin-angiotensin system. [20] [21] [22] Accordingly, VDR-deficient mice display high renin and Ang-II levels and develop hypertension. 20 In addition to regulating the components involved in synthesizing Ang-II, calcitriol also alters the expression of Ang-II AT1 receptors in several target tissues. 23, 24 Therefore, vitamin D 3 seems to affect on a range of cellular and molecular mechanisms of importance to AAA pathogenesis. 25 It is uncertain, however, whether VDR activation can affect dissecting AAA promoted by Ang-II, and the vascular inflammatory and angiogenic response associated with this disease.
In an attempt to find more effective therapeutic strategies to halt the progression of AAA, this study aimed to examine the effect of calcitriol on Ang-II-induced dissecting AAA development in apoE −/− mice. We demonstrate for the first time that calcitriol treatment significantly attenuates dissecting AAA formation. Calcitriol-cotreated mice exhibit reduced macrophage infiltration, and MMP and chemokine expression in the suprarenal aortic walls, which seem to be mediated through activation of VDR-retinoid X receptor alpha (RXRα) interactions. We also show that VDR activation inhibits Ang-II-induced mononuclear leukocyte-endothelial cell interactions, morphogenesis, and endothelial release of proangiogenic chemokines.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Calcitriol Treatment Inhibits Ang-II-Induced Dissecting Aneurysm Formation
ApoE −/− mice were infused subcutaneously with Ang-II (n=36) or saline (n=10) for 28 days. Ang-II-infused mice received orally vehicle (n=12) or calcitriol administered every other day at a dose of 0.1 μg/kg (n=12) or 1 μg/kg (n=12; Figure 1 ). Within the initial 14 days of treatments, 2 (17%) Ang-II-infused apoE −/− mice and 2 (17%) Ang-II plus low-dose calcitriol-treated mice died as a result of rupture of the aorta in the suprarenal abdominal region, whereas no deaths occurred in mice treated with calcitriol at the higher dose ( Figure 1B ). As expected, no dissecting aneurysms were present in saline-infused control mice at day 28 ( Figure 1C and 1D ). Ang-II-infused apoE −/− mice showed a larger maximal external diameter of the suprarenal aorta than saline-infused mice, which was significantly reduced in mice treated with 1-μg/kg calcitriol ( Figure 1C , P<0.05). On the basis of the classification system of Daugherty et al, 26 the dissecting aneurysms induced by Ang-II were more severe than in those cotreated with calcitriol (1 μg/kg; Figure 1D , P<0.05). Furthermore, the increased diameter and area of ascending aortas induced by Ang-II infusion was significantly reduced in calcitriol-cotreated (1 μg/kg) mice ( Figure IA and IB in the online-only Data Supplement, P<0.05). Calcitriol administration did not provoke changes in the systolic blood pressure or the lipid profile in apoE −/− mice chronically infused with Ang-II ( Table I in 
Calcitriol Reduces Leukocyte Infiltration and Neovascularization in Dissecting AAA Induced by Ang-II
Inflammation and angiogenesis are prominent features of AAA. 1, 27 Immunohistochemical analysis of suprarenal aortic sections showed that Ang-II infusion for 28 days promoted leukocyte recruitment of CD68 + cells in the adventitia and media (Figure 2A ), which was significantly reduced in calcitriolcotreated mice (18.2±5.4% versus 29.2±4.1%, P<0.05; Figure  2B ). By contrast, neutrophils were undetected in any group as demonstrated by negative myeloperosidase staining ( Figure 2A ). In addition, the increased mRNA expression of the chemokines (C-C motif) ligand 2 (CCL2) (monocyte chemoattractant protein-1; Figure 2C ), (C-C motif) ligand 5 (CCL5) (regulated on activation normal T cell expressed and secreted; Figure 2D ), and (C-X-C motif) ligand 1 (CXCL1) (growth-related oncogene-α; Figure 2E ) in suprarenal aortas from Ang-II-infused apoE −/− mice was significantly reduced in calcitriol-cotreated mice.
When compared with the control group, Ang-II-infused animals presented a significant increase in CD31 + capillary vessels ( Figure 2F and 2G) and also expression of vascular endothelial growth factor (VEGF) mRNA ( Figure 2H ) in aortic tissue. Mice cotreated with calcitriol had less capillary formation and VEGF mRNA expression in the suprarenal aortas than Ang-II-infused animals ( Figure 2G and 2H, P<0.05).
Calcitriol Modulates Ang-II-Induced Extracellular Matrix Degradation in Dissecting AAA
Histological examination of Ang-II-induced dissecting AAA revealed a structural deformity within the adventitia of the Because MMPs are intimately involved in extracellular matrix destruction and aortic wall remodeling in AAA, 28 we questioned the effect of calcitriol on the balance between MMP-2 and MMP-9 and their endogenous inhibitor tissue inhibitor of metalloproteinases (TIMP-1). Immunohistochemistry revealed that Ang-II-infused mice had higher expression of MMP-2 and MMP-9 and also TIMP-1 protein than vehicle-treated mice in the suprarenal aorta ( Figure 3A ), and this correlated with a significant increase in mRNA expression ( Figure 3B through 3D, P<0.05). By contrast, MMP-2 ( Figure 3A , P<0.05) and MMP-9 expression ( Figure 3C , P<0.05) was lower in calcitriol-cotreated mice, whereas TIMP-1 expression was higher ( Figure 3D , P<0.05) in suprarenal aortas.
Calcitriol attenuates extracellular signal-regulated kinases 1/2 (ERK1/2), p38 mitogen-activated protein kinase (p38 MAPK), and nuclear factor-κB (NF-κB) phosphorylation in Ang-II-induced dissecting AAA.
Activation of MAPK signaling, including ERK1/2, p38 MAPK, and NF-κB, is implicated in AAA pathogenesis. 29, 30 We therefore evaluated the impact of calcitriol cotreatment on these pathways in suprarenal aneurysmal tissue. Western blot analysis of the suprarenal aorta revealed significantly higher levels of ERK1/2 ( Figure 4A ), p38 MAPK ( Figure 4B ), and p65 ( Figure 4C ) phosphorylation in apoE −/− mice subjected to Ang-II infusion for 28 days than in vehicle-treated mice. Phosphorylation of ERK1/2, p38 MAPK, and NF-κB was significantly reduced in the suprarenal aortas of calcitriolcotreated mice (Figure 4 , P<0.05).
Effects of Calcitriol Treatment on Ang-II-Induced Vascular Responses in the Early Phase of Dissecting AAA Formation
Additional studies were performed to investigate whether calcitriol treatment modulated the early phase of Ang-II-induced vascular dysfunction. CD68-positive cells or neutrophils (myeloperosidase) were not detected in the suprarenal aortas at 5 days after Ang-II infusion. ( Figure IIIA and IIIB in the online-only Data Supplement). However, mRNA expression of CCL2, CCL5, and CXCL1 was increased in the suprarenal aortas of Ang-II-infused apoE −/− mice, but not in calcitriolcotreated mice ( Figure IIIC Elastin fibers and smooth muscle cells in aorta segments of Ang-II-infused animals seemed intact in all treatment .05 vs Ang-II-infused animals. D, Aneurysm severity (stages I to IV) was scored using a classification scheme similar to the one described previously. 26 Stage IV was attributed to ruptured aneurysms. Reverse-transcription polymerase chain reaction analysis of VDR expression in the suprarenal and ascending aorta of mice infused for 5 days with Ang-II revealed that although a modest increase was detected in calcitriol-treated animals, none of the treatments significantly altered VDR expression ( Figure VE in the online-only Data Supplement, P>0.05). Because activation of VDR by its ligand can result in heterodimerization with other nuclear receptors, such as RXRα, 31 we performed immunoprecipitation experiments to investigate the potential involvement of VDR-RXRα heterodimer complexes in the responses elicited by calcitriol. Immunoprecipitation was performed in mouse aortas using an anti-RXRα antibody for immunoprecipitation and an anti-VDR antibody for Western blotting. An augmented VDR-RXRα interaction was observed in both suprarenal and ascending aortas of calcitriol-treated mice ( Figure VF 
Calcitriol Decreases Mononuclear Leukocyte-Endothelial Cell Interactions and Morphogenesis Induced by Ang-II
To connect our observations in mice to humans, we investigated the effect of calcitriol on Ang-II-induced vascular inflammation and angiogenesis in primary human umbilical vein endothelial cell (HUVEC) cultures. We first evaluated mononuclear leukocyte-endothelial cell interactions in vitro using a dynamic flow chamber assay. 32 Freshly isolated human mononuclear cells were perfused across HUVEC monolayers stimulated or not with Ang-II (1 μmol/L) for 24 hours and adhesion was measured. Mononuclear leukocyte adhesion to endothelial cells was significantly higher in cells stimulated with Ang-II than in cells treated with vehicle (0.01% DMSO [dimethyl sulfoxide]; Figure VI Given our findings of increased aorta microvessel formation in mice infused with Ang-II for 28 days, we further evaluated the effect of calcitriol on angiogenesis using an in vitro endothelial differentiation assay. 33, 34 As anticipated, Ang-II provoked a significant increase in HUVEC capillary tube formation, and this was inhibited by calcitriol pretreatment in a concentration-dependent manner ( Figure VIB 
Calcitriol Decreases Ang-II-Induced Endothelial Production of Chemokines and VEGF
Ang-II signaling through AT1 receptor interactions induces the production and release of different CC and CXC chemokines [34] [35] [36] and VEGF. 34 To determine whether calcitriol affected the levels of these factors, we collected conditioned media from treated cells and performed ELISA. A significant increase was detected in the levels of CCL2, CCL5, CXCL1, and VEGF in culture medium of HUVEC subjected to Ang-II stimulation for 24 hours ( Figure VIC 
VDR and RXRα Are Involved in the Anti-Inflammatory and Antiangiogenic Activity Exerted by Calcitriol in Human Endothelial Cells
To explore the underlying mechanisms for the observed effects of calcitriol, we investigated the potential involvement of the VDR in these responses. We used RNA interference to specifically downregulate VDR expression. HUVEC transfected with an siRNA targeting VDR demonstrated a >75% reduction in VDR protein levels after 48 hours relative to control siRNA-transfected cells ( Figure 5A, P<0.05 ). Of note, VDR silencing abolished the inhibitory effects of calcitriol (100 nmol/L) on mononuclear leukocyte arrest ( Figure 5B ), tubulogenesis ( Figure 5C ), and cytokine release ( Figure 5D through 5G) induced by Ang-II in HUVEC.
We used an identical approach to silence RXRα expression ( Figure 6A ). Consistent with the results for VDR silencing, RXRα silencing blocked the inhibitory effects elicited by the VDR ligand (100 nmol/L) on leukocyte arrest ( Figure 6B , P<0.05) and tubulogenesis ( Figure 6C , P<0.05) in HUVEC stimulated with Ang-II.
To extend these findings, we performed immunocytochemistry using antibodies to VDR and RXRα. Although significant amounts of unliganded VDR and RXRα were found in the cytoplasm of endothelial cells, calcitriol exposure resulted in the translocation of VDR and RXRα into the nucleus ( Figure 6D ). As expected, immunoprecipitation assays revealed an enhanced VDR-RXRα interaction in the presence of calcitriol ( Figure 6E ).
Calcitriol Inhibits the Activation of Ang-II-Induced MAPK Signaling Pathways in Human Endothelial Cells
Finally, as ERK1/2, p38 MAPK, and NF-κB signaling pathways seem to play a role in Ang-II-induced dissecting AAA formation, we examined their potential involvement in the inflammatory and angiogenic response provoked by Ang-II in human endothelial cells. 
Discussion
Vitamin D 3 deficiency is emerging as a new cardiovascular risk factor associated with the development of AAA. 14 Indeed, clinical studies suggest that low levels of vitamin D 3 are associated with inflammation and the consequent endothelial dysfunction, 37 and correlate with AAA development and enhanced aortic diameters. 14 By contrast, VDR activation seems to exert anti-inflammatory properties, 18 and it is effective at inhibiting atherosclerosis lesion formation in animal models. 15, 38, 39 Despite these findings, the direct effects of vitamin D 3 on AAA development are largely unknown. This study was designed to evaluate the effect of orally administered calcitriol on dissecting AAA development in the Ang-II-infused apoE −/− mouse model. An imbalance of renin-angiotensin system is associated with AAA pathogenesis. 2, 40 In this study, we provide evidence that oral calcitriol treatment for 28 days inhibits dissecting AAA formation induced by Ang-II and also reduces macrophage infiltration. It is well recognized that macrophages play critical roles in the pathophysiology of AAA by secreting inflammatory chemokines/cytokines and MMPs, which lead to aortic structural disruption. 2, 6, 41 We found that suprarenal aortic expression of the inflammatory markers CCL2, CCL5, and CXCL1 were increased in response to Ang-II infusion in both the acute (5 days) and the chronic (28 days) phases, and these increases were diminished in calcitriol-cotreated mice. Consistent with our data, the calcitriol treatment decreased vascular cell adhesion molecule-1, interferon-γ, and CCL2 expression in atherosclerotic plaques in a murine model of atherosclerosis, leading to reduced lesion formation. 38 In this context, high levels of some of these chemokines and their receptors have been detected in the microenvironment of the AAA wall in humans, 42, 43 and in experimental models. 44 Indeed, CCR2 deficiency or dual blockade of CCR1/CCR5 receptors drastically reduces the recruitment of monocytes into the aortic lesion, inhibits MMPs and neovascularization, and preserves aortic wall structure, resulting in attenuated aneurysm development. 45, 46 A growing body of evidence suggests the potential interplay between angiogenesis and inflammation, 47 and new microvessel formation in aortic aneurysmal disease is related to the risk of rupture and complications. 27 Because newly formed blood microvessels facilitate the continuous recruitment of immune cells that release a variety of key mediators, such as proinflammatory and proangiogenic chemokines and growth factors, it is plausible to suggest that exacerbation of inflammation may be directly involved in the amplification of the angiogenic process. 47 Of interest, suprarenal aortic neovascularization and VEGF levels were unchanged during the acute phase of dissecting AAA formation; however, a marked increase in angiogenesis and VEGF levels were detected during the chronic phase of Ang-II-induced dissecting AAA. It is well established that Ang-II stimulation of vascular endothelial cells results in the production of an array of leukocyte-recruiting chemokines and VEGF. 36, 48, 49 CCL2 and CCL5 together with the ELR + CXC chemokine CXCL1/ growth-related oncogene-α are involved in neovascularization, 45, 50, 51 and previous data by our group revealed that CCL2, CCL5, and VEGF are likely key molecules in the angiogenic activity elicited by Ang-II. 34 Our present study suggests that the marked increased of VEGF and neovascularization in dissecting AAA could be attributable to the cellular proliferation and intense infiltration of the suprarenal aortic walls by inflammatory cells. Previous reports demonstrated that calcitriol can suppress VEGF-induced endothelial cell sprouting and angiogenesis in vivo and in vitro. 17 We found that the suparenal aortas of chronic calcitriol-treated mice presented a marked reduction in neovascularization and VEGF levels. These changes might be because of the reduction in leukocyte infiltration provoked by calcitriol because inflammatory cells including monocytes/macrophages recruited during aortic aneurysm development are an important source of VEGF. 52 Dysregulation of MMP production and activity represents an additional major mechanism in the initiation and the progression of AAA. 2, 41 MMPs are released by endothelial cells and smooth muscle cells, but also by infiltrating inflammatory cells, predominantly macrophages, and contribute to medial smooth muscle cell apoptosis, degradation of elastin and subsequently AAA formation. 2, 41 MMP activity is modulated by TIMPs, 41 and the MMP/TIMP ratio is critical for controlling tissue damage. 53 In agreement with previous reports, 54 we found an increase in MMP-9 in suprarenal aortas before dissecting AAA formation and 28 days after Ang-II infusion; however, MMP-2 expression was prominent only at the later stages of dissecting AAA development. Interestingly, calcitriol-cotreated mice had reduced medial elastin destruction together with a reduction in MMP-2 and MMP-9 and an increase in TIMP-1 levels in suprarenal aortas. Consistent with our data, activation of VDR can downregulate MMP-2 and MMP-9 and upregulate TIMP-1 in several vascular cells and tissues. [55] [56] [57] Therefore, our current findings suggest that VDR activation may play an important role in the preservation of vessel wall integrity.
AT1 receptors are expressed in endothelial cells. 58 Under dynamic flow conditions or during endothelial differentiation in vitro, pretreatment of endothelial cells with calcitriol resulted in significant reductions in leukocyte arrest and tubulogenesis induced by Ang-II. Proinflammatory and proangiogenic effects of Ang-II through its interaction with AT1 receptors have been described both in vitro and in animal models. 3, 34, 48 However, although previous studies have demonstrated that whole-body AT1a receptor deficiency reduces aneurysms, 59 depletion of AT1a receptors in endothelial or smooth muscle cells did not affect Ang-II-induced dissecting AAA in mice. 60 Therefore, the main cell type stimulated by Ang-II to induce dissecting AAA remains to be determined.
On interaction with calcitriol, VDR acts as a transcription factor through its binding to distinct responsive elements, probably through the formation of heterodimers with RXR receptors. 31, 61 Our data in apoE −/− mice show that VDR expression in the suprarenal or ascending aorta remained unchanged after Ang-II infusion or calcitriol cotreatment. However, VDR-RXRα interaction was markedly increased in calcitriol-treated mice. Similarly, knockdown of endothelial RXRα reversed the inhibitory effects mediated by calcitriol on Ang-II-induced mononuclear leukocyte adhesion and morphogenesis, and immunoprecipitation studies revealed a clear interaction between VDR and RXR in human endothelial cells treated with calcitriol. Given that RXRα activation can inhibit mononuclear cell adhesion 62 and exert antiangiogenic properties, 63 it seems probable that calcitriol functions, in part, via VDR-RXRα heterodimerization.
Activation of ERK1/2, p38 MAPK, and NF-κB were detected in the acute and the chronic phase of Ang-II infusion in apoE −/− mice. ERK1/2 and p38 MAPK are upstream regulators of NF-κB, and the latter can regulate the expressions of numerous genes including those related to proinflammatory and proangiogenic responses in AAA development. 64, 65 Along this line, activation of ERK1/2 and p38 is associated with MMP upregulation and subsequent AAA formation. 6, 66, 67 Recently, endothelial selective blockade of NF-κB signaling in transgenic mice reduced Ang-II-induced dissecting AAA formation, which was associated with diminished macrophage infiltration and decreased expression of inflammatory markers (CCL2 and interleukin-6) and MMPs (MMP2 and MMP9) in the aortic wall. 29 Of interest, phosphorylation of ERK1/2, p38 MAPK, and NF-κB was reduced in the suparenal aortas of apoE −/− mice cotreated with calcitriol for 28 days. In addition, diminished activation of ERK1/2 and NF-κB, but not p38 MAPK, was detected after acute calcitriol treatment. NF-κB-mediated signaling is thought to be relevant for the expression of chemokines 68 and VEGF 65 in the endothelium. Furthermore, MAPK and NF-κB signaling pathways are modulated by VDR ligands. 18, 69 Overall, the vascular protective effects displayed by VDR activation indicates that the impaired activation of the NF-κB pathway limits the release of inflammatory/proangiogenic molecules, resulting in blunted endothelial activation.
Finally, it is important to note that the doses and regimen of calcitriol used in this study were based on previous reports, with doses ranging from 0.1 to 10 μg/kg every other day in mice with no toxicity effects or hypercalcemia. 38, 70, 71 In humans, doses of calcitriol 0.5 μg/kg or 38 μg/d showed minimal toxicity when used as intermittent therapy in clinical cancer trials. 72 To minimize the calcemic side effects, a large number of vitamin D analogs with tissue-specific effects and low calcemic side effects have been developed in recent years. 73 However, whether calcitriol at the doses used in our study in mice can offer a safe and effective approach for AAA in humans remains an open question and further clinical research with selective nonhypercalcemic VDR ligands is needed.
In conclusion, this study provides the first evidence that chronic treatment with calcitriol reduces Ang-II-induced dissecting AAA formation in mice. These effects are associated with a reduced inflammatory response and regulation of extracellular matrix homeostasis through VDR-RXRα heterodimerization. In light of these results, activation of VDR may represent a promising therapeutic target for AAA treatment.
